| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 23 | 2024 | 2443 | 2.550 |
Why?
|
| Carcinoma, Transitional Cell | 9 | 2024 | 1011 | 1.980 |
Why?
|
| Urologic Neoplasms | 4 | 2021 | 208 | 1.820 |
Why?
|
| Antibodies, Monoclonal | 8 | 2020 | 4495 | 1.350 |
Why?
|
| Macrophages | 9 | 2017 | 1376 | 1.150 |
Why?
|
| Kidney Neoplasms | 16 | 2024 | 3150 | 1.130 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2024 | 2417 | 1.120 |
Why?
|
| Urothelium | 3 | 2024 | 272 | 1.120 |
Why?
|
| CTLA-4 Antigen | 7 | 2021 | 681 | 1.040 |
Why?
|
| DNA, Bacterial | 6 | 2010 | 604 | 1.030 |
Why?
|
| Immunoconjugates | 2 | 2023 | 314 | 0.810 |
Why?
|
| Folic Acid Antagonists | 1 | 2022 | 48 | 0.800 |
Why?
|
| Carcinoma | 3 | 2020 | 2623 | 0.780 |
Why?
|
| Lipopolysaccharides | 6 | 2003 | 593 | 0.760 |
Why?
|
| B7-H1 Antigen | 7 | 2021 | 1072 | 0.760 |
Why?
|
| Immunotherapy | 12 | 2023 | 3539 | 0.760 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2020 | 1089 | 0.710 |
Why?
|
| Interferon-gamma | 6 | 2016 | 1180 | 0.700 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2021 | 1335 | 0.700 |
Why?
|
| Ipilimumab | 6 | 2021 | 759 | 0.560 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 42 | 0.550 |
Why?
|
| B7 Antigens | 1 | 2017 | 84 | 0.550 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 14653 | 0.540 |
Why?
|
| Cystectomy | 3 | 2021 | 632 | 0.540 |
Why?
|
| Nitric Oxide Synthase | 4 | 2000 | 329 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 3391 | 0.480 |
Why?
|
| Ureteral Neoplasms | 3 | 2022 | 236 | 0.480 |
Why?
|
| Immunomodulation | 1 | 2016 | 253 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 16606 | 0.420 |
Why?
|
| Autoantibodies | 2 | 2019 | 600 | 0.410 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 312 | 0.400 |
Why?
|
| Colitis | 3 | 2019 | 344 | 0.390 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 2398 | 0.360 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 115 | 0.360 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2021 | 156 | 0.350 |
Why?
|
| Humans | 67 | 2024 | 271636 | 0.350 |
Why?
|
| Cancer Vaccines | 2 | 2012 | 751 | 0.350 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 2999 | 0.330 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2021 | 686 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 5420 | 0.320 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 484 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2010 | 599 | 0.310 |
Why?
|
| BCG Vaccine | 2 | 2021 | 426 | 0.300 |
Why?
|
| Cisplatin | 4 | 2023 | 2497 | 0.290 |
Why?
|
| Carcinoma, Medullary | 2 | 2020 | 248 | 0.280 |
Why?
|
| Signal Transduction | 11 | 2024 | 12219 | 0.270 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 555 | 0.270 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2010 | 356 | 0.260 |
Why?
|
| Nitric Oxide | 2 | 1999 | 665 | 0.250 |
Why?
|
| Prostatic Neoplasms | 3 | 2023 | 5996 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2024 | 1264 | 0.250 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2002 | 294 | 0.240 |
Why?
|
| Macrophage Activation | 3 | 2001 | 151 | 0.240 |
Why?
|
| Animals | 22 | 2024 | 62757 | 0.240 |
Why?
|
| Cell Dedifferentiation | 2 | 2024 | 101 | 0.230 |
Why?
|
| T-Lymphocytes | 5 | 2020 | 3934 | 0.230 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 629 | 0.230 |
Why?
|
| Melanoma | 3 | 2020 | 5591 | 0.230 |
Why?
|
| SMARCB1 Protein | 2 | 2024 | 109 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 5209 | 0.230 |
Why?
|
| Neoplasms | 8 | 2024 | 15903 | 0.220 |
Why?
|
| Immune System Diseases | 1 | 2023 | 65 | 0.220 |
Why?
|
| Urinary Tract | 1 | 2023 | 86 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 2672 | 0.210 |
Why?
|
| Kynurenine | 1 | 2023 | 67 | 0.210 |
Why?
|
| Interleukin-6 | 3 | 2024 | 1066 | 0.210 |
Why?
|
| Male | 30 | 2024 | 128836 | 0.210 |
Why?
|
| DNA Copy Number Variations | 3 | 2024 | 1555 | 0.200 |
Why?
|
| Gene Expression Regulation | 3 | 2006 | 4193 | 0.200 |
Why?
|
| Mice | 16 | 2024 | 36006 | 0.200 |
Why?
|
| Retrospective Studies | 17 | 2024 | 39731 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 1657 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2002 | 1613 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 7971 | 0.200 |
Why?
|
| Escherichia coli | 3 | 2003 | 1308 | 0.190 |
Why?
|
| Toxicity Tests | 1 | 2021 | 51 | 0.190 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2022 | 180 | 0.190 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 5180 | 0.190 |
Why?
|
| Quinolines | 1 | 2024 | 402 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2020 | 272 | 0.180 |
Why?
|
| Middle Aged | 22 | 2024 | 90349 | 0.180 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 600 | 0.180 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 14868 | 0.180 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2001 | 157 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 296 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 2 | 2020 | 692 | 0.180 |
Why?
|
| Aged | 18 | 2024 | 73421 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2021 | 108 | 0.170 |
Why?
|
| Interferon-beta | 1 | 2000 | 109 | 0.170 |
Why?
|
| Female | 29 | 2024 | 148992 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4888 | 0.170 |
Why?
|
| Cryosurgery | 1 | 2021 | 186 | 0.170 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2019 | 78 | 0.170 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 3852 | 0.170 |
Why?
|
| Adult | 16 | 2024 | 81791 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2016 | 595 | 0.160 |
Why?
|
| Macrophages, Peritoneal | 1 | 1998 | 76 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 316 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 10354 | 0.160 |
Why?
|
| Prognosis | 9 | 2021 | 22525 | 0.150 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 469 | 0.150 |
Why?
|
| Transcriptome | 2 | 2024 | 1940 | 0.150 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 10743 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 161 | 0.150 |
Why?
|
| Treatment Outcome | 12 | 2024 | 33846 | 0.150 |
Why?
|
| Cell Line | 8 | 2006 | 5431 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 741 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 619 | 0.140 |
Why?
|
| Tattooing | 1 | 2016 | 16 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1055 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2016 | 93 | 0.130 |
Why?
|
| DNA Replication | 1 | 2020 | 772 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 272 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2016 | 115 | 0.130 |
Why?
|
| Immune System | 2 | 2018 | 277 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 864 | 0.130 |
Why?
|
| Genomics | 3 | 2021 | 2830 | 0.130 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 759 | 0.120 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 485 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 3416 | 0.120 |
Why?
|
| Disease Progression | 3 | 2024 | 6905 | 0.120 |
Why?
|
| Clonal Evolution | 1 | 2016 | 251 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 1142 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2000 | 255 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1387 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1742 | 0.120 |
Why?
|
| DNA-Binding Proteins | 4 | 2003 | 5067 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 1998 | 961 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2016 | 385 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 7222 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 704 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2000 | 1660 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1427 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2024 | 7817 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1085 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 1004 | 0.110 |
Why?
|
| Pneumonia | 1 | 2019 | 798 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5566 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2020 | 2254 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 2034 | 0.110 |
Why?
|
| Drug Synergism | 3 | 2020 | 1364 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 5113 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2024 | 9093 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2003 | 81 | 0.100 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5328 | 0.100 |
Why?
|
| Mutation | 6 | 2024 | 15913 | 0.100 |
Why?
|
| Prostatectomy | 1 | 2017 | 1006 | 0.100 |
Why?
|
| Sarcoma | 2 | 2020 | 1842 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 2668 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 13989 | 0.100 |
Why?
|
| CpG Islands | 2 | 2006 | 662 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1824 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 4963 | 0.100 |
Why?
|
| DNA Mutational Analysis | 3 | 2024 | 2365 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 31032 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 1136 | 0.090 |
Why?
|
| Penile Neoplasms | 1 | 2013 | 182 | 0.090 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2010 | 52 | 0.090 |
Why?
|
| Anilides | 2 | 2024 | 296 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3077 | 0.090 |
Why?
|
| Nephroureterectomy | 2 | 2022 | 47 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 12008 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2022 | 13385 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2020 | 2973 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 967 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1838 | 0.080 |
Why?
|
| Antibodies | 1 | 2012 | 819 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2023 | 9042 | 0.080 |
Why?
|
| Cytokines | 2 | 2016 | 2837 | 0.080 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2010 | 126 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2003 | 911 | 0.080 |
Why?
|
| ras Proteins | 1 | 2013 | 802 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 1013 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 540 | 0.080 |
Why?
|
| Obesity | 1 | 2020 | 2952 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 4070 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5779 | 0.070 |
Why?
|
| Enzyme Induction | 2 | 1998 | 262 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 1728 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2000 | 3262 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2016 | 2457 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2017 | 247 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 5804 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 18016 | 0.070 |
Why?
|
| Peptidoglycan | 1 | 2006 | 20 | 0.070 |
Why?
|
| Immune Tolerance | 2 | 2021 | 431 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2020 | 380 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 3976 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2024 | 1574 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5246 | 0.060 |
Why?
|
| Nephrectomy | 2 | 2023 | 808 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 7463 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 234 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4805 | 0.060 |
Why?
|
| Endotoxins | 2 | 2003 | 97 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2495 | 0.060 |
Why?
|
| Transcription Factors | 1 | 1998 | 5504 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2013 | 2383 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2021 | 9467 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3924 | 0.060 |
Why?
|
| Interferon Regulatory Factor-1 | 2 | 2000 | 54 | 0.060 |
Why?
|
| Enterococcus faecalis | 1 | 2002 | 58 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 362 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 716 | 0.050 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2023 | 109 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 230 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2023 | 377 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 889 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2024 | 1074 | 0.050 |
Why?
|
| Receptors, Thrombin | 1 | 2001 | 19 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2002 | 163 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2000 | 4984 | 0.050 |
Why?
|
| Half-Life | 1 | 2001 | 269 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 408 | 0.050 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2020 | 28 | 0.050 |
Why?
|
| Telomerase | 1 | 2024 | 542 | 0.050 |
Why?
|
| Keratin-5 | 1 | 2020 | 57 | 0.050 |
Why?
|
| Keratin-6 | 1 | 2020 | 40 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2020 | 4358 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2021 | 183 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 36 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 95 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2000 | 407 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1999 | 172 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 145 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 1139 | 0.040 |
Why?
|
| Culture Media | 1 | 2000 | 338 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2000 | 162 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2021 | 9323 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2001 | 634 | 0.040 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 1998 | 7 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 771 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 603 | 0.040 |
Why?
|
| Cycloheximide | 1 | 1998 | 111 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2023 | 7292 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1998 | 71 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 420 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 508 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2024 | 2314 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 589 | 0.040 |
Why?
|
| Phenotype | 2 | 2020 | 6510 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2021 | 600 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 331 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 621 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 1998 | 257 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 705 | 0.040 |
Why?
|
| Interferons | 1 | 1999 | 300 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 318 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 683 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2023 | 1378 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2000 | 504 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 688 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 3070 | 0.040 |
Why?
|
| Phosphoproteins | 2 | 2000 | 1230 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 524 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 64 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2024 | 1599 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 10259 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2023 | 909 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 726 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 1146 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 563 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 5601 | 0.040 |
Why?
|
| Kinetics | 1 | 2000 | 2242 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 751 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 191 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 685 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 49 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2001 | 1568 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 896 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1999 | 588 | 0.030 |
Why?
|
| Biomarkers | 2 | 2019 | 5111 | 0.030 |
Why?
|
| Proteomics | 1 | 2023 | 1436 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 655 | 0.030 |
Why?
|
| Lymphadenopathy | 1 | 2016 | 94 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 327 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1408 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 845 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 13116 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2853 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 678 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1311 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2000 | 1740 | 0.030 |
Why?
|
| Young Adult | 3 | 2021 | 22094 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 815 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 835 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7788 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 1588 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 2649 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 544 | 0.030 |
Why?
|
| Patient Selection | 1 | 2021 | 2043 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 1482 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 745 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 1125 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 1566 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 3670 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 2468 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 2202 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 5195 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 2624 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 4370 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2015 | 957 | 0.020 |
Why?
|
| Pyrroles | 1 | 2015 | 592 | 0.020 |
Why?
|
| Gene Expression | 2 | 2013 | 3688 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 2349 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 5744 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6434 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1053 | 0.020 |
Why?
|
| Models, Biological | 1 | 1998 | 3223 | 0.020 |
Why?
|
| Indoles | 1 | 2015 | 1034 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1999 | 6488 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 1999 | 3472 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6230 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 1998 | 5838 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 6876 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1827 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12530 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6266 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3423 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 94 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4391 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2019 | 2912 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 1331 | 0.020 |
Why?
|
| Apoptosis | 1 | 2020 | 7834 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2006 | 138 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 252 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 1892 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 5856 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15254 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 4967 | 0.010 |
Why?
|
| Galactosamine | 1 | 2002 | 6 | 0.010 |
Why?
|
| Receptor, PAR-2 | 1 | 2001 | 6 | 0.010 |
Why?
|
| Receptor, PAR-1 | 1 | 2001 | 32 | 0.010 |
Why?
|
| HLA-G Antigens | 1 | 1999 | 20 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1999 | 83 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2001 | 347 | 0.010 |
Why?
|
| U937 Cells | 1 | 1999 | 179 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1999 | 92 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2001 | 285 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 1842 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 2532 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 32609 | 0.010 |
Why?
|
| Child | 1 | 2016 | 30401 | 0.010 |
Why?
|
| Binding Sites | 1 | 1999 | 2298 | 0.010 |
Why?
|
| Peptides | 1 | 2001 | 1528 | 0.010 |
Why?
|
| Calcium | 1 | 2001 | 1594 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 3165 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 5499 | 0.010 |
Why?
|
| DNA | 1 | 1999 | 3088 | 0.010 |
Why?
|
| Pregnancy | 1 | 1999 | 8089 | 0.000 |
Why?
|